SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Schiöth Helgi B.)
 

Sökning: WFRF:(Schiöth Helgi B.) > A pharmacogenetic r...

A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants

Kanders, Sofia H. (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi
Pisanu, Claudia (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi,Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
Bandstein, Marcus, 1988- (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi
visa fler...
Jonsson, Jörgen (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi
Castelao, Enrique (författare)
Pistis, Giorgio (författare)
Gholam-Rezaee, Mehdi (författare)
Eap, Chin B. (författare)
Preisig, Martin (författare)
Schiöth, Helgi B. (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi,Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia
Mwinyi, Jessica (författare)
Uppsala universitet,Schiöth: Funktionell farmakologi
visa färre...
 (creator_code:org_t)
2019-10-16
2020
Engelska.
Ingår i: Drug development research. - : John Wiley & Sons. - 0272-4391 .- 1098-2299. ; 81:1, s. 102-113
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The severity of symptoms as well as efficacy of antidepressants in major depressive disorder (MDD) is modified by single nucleotide polymorphisms (SNPs) in different genes, which may contribute in an additive or synergistic fashion. We aimed to investigate depression severity in participants with MDD under treatment with antidepressants in relation to the combinatory effect of selected genetic variants combined using a genetic risk score (GRS). The sample included 150 MDD patients on regular AD therapy from the population‐based Swiss PsyCoLaus cohort. We investigated 44 SNPs previously associated with antidepressant response by ranking them with regard to their association to the Center for Epidemiologic Studies Short Depression Scale (CES‐D) score using random forest. The three top scoring SNPs (rs12248560, rs878567, rs17710780) were subsequently combined into an unweighted GRS, which was included in linear and logistic regression models using the CES‐D score, occurrence of a major depressive episode (MDE) during follow‐up and regular antidepressant treatment during the 6 months preceding follow‐up assessment as outcomes. The GRS was associated with MDE occurrence (p = .02) and ln CES‐D score (p = .001). The HTR1A rs878567 variant was associated with ln CES‐D after adjustment for demographic and clinical variables [p = .02, lower scores for minor allele (G) carriers]. Additionally, rs12248560 (CYP2C19 ) CC homozygotes showed a six‐fold higher likelihood of regular AD therapy at follow‐up compared to minor allele homozygotes [TT; ultrarapid metabolizers (p = .03)]. Our study suggests that the cumulative consideration of pharmacogenetic risk variants more reliably reflects the impact of the genetic background on depression severity than individual SNPs.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

depression
genetic risk score
pharmacogenetics
random forest
treatment with antidepressants

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy